What to know before starting GLP-1 medication

Realistic expectations

Clinical trials show that, on average, patients lose approximately 15% of body weight during active GLP-1 treatment, with substantial individual variation. Loss is gradual — typically over months — and depends on adherence, dosing, and lifestyle context.

GLP-1 medications work by influencing appetite, satiety, and gastric emptying. They are not a shortcut around metabolic biology, and they don't build the eating and movement patterns that protect results long-term.

Common side effects

Nausea, vomiting, diarrhea, and constipation are the most commonly reported side effects, especially during dose titration. Many patients find these manageable with dietary adjustments and dose pacing.

Less common but more serious risks include pancreatitis, gallbladder disease, and others. Your clinician discusses risks specific to your health profile during evaluation and continues to monitor you throughout treatment.

Speak with your clinician promptly about severe or persistent symptoms, especially severe abdominal pain, vision changes, or signs of an allergic reaction.

Lifestyle changes that support outcomes

Protein-first nutrition helps preserve lean muscle mass during the appetite suppression of GLP-1 therapy. Inadequate protein intake during weight loss can reduce metabolic rate and increase rebound risk after discontinuation.

Resistance training and structured movement build the muscle mass and habits that protect long-term results. Walking is a useful baseline; strength programming matters more than people expect.

Behavior coaching — accountability check-ins, habit formation, and addressing emotional eating patterns — is the layer that makes results stick after medication ends.

Long-term considerations

Discontinuation outcomes are well-documented: clinical trial data shows that, on average, patients regain approximately two-thirds of lost weight within 12 months of stopping GLP-1 medication without ongoing structured support.

A taper plan should be discussed from the start — not improvised when insurance lapses or supply changes. BridgeWell's Maintain plan exists specifically for this transition, with clinician-supervised tapering and intensified coaching during dose reduction.

Long-term continuation of GLP-1 therapy is also a clinically valid choice for some patients. The decision to taper or continue is yours and your clinician's, made with current evidence and your specific situation in mind.

Cost and insurance

GLP-1 medications are expensive. Some commercial insurance plans cover them for type 2 diabetes; coverage for weight management specifically is more variable. Your clinical partner can coordinate with insurance where coverage exists.

Many members pay out-of-pocket through the partner pharmacy network. BridgeWell's enrollment fee is paid directly to BridgeWell and covers program enrollment, not medication.

Frequently asked